Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has been approved for the treatment of obese or overweight patients associated with cardiovascular risk factors. In this article it is compared the effects of rimonabant treatment in obese patients with cardiovascular risk factors to usual obesity pharmacological treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770455 | PMC |
| http://dx.doi.org/10.1186/1758-5996-1-18 | DOI Listing |
Publication Analysis
Top Keywords
treatment obese
8
cardiovascular risk
8
risk factors
8
endocanabinnoid system
4
system diabetes
4
diabetes critical
4
critical analyses
4
analyses studies
4
studies conducted
4
conducted rimonabant
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!